IMPACT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS ON LONG-TERM - - PowerPoint PPT Presentation

impact of anticoagulants
SMART_READER_LITE
LIVE PREVIEW

IMPACT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS ON LONG-TERM - - PowerPoint PPT Presentation

IMPACT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS ON LONG-TERM MORTALITY AFTER HIP FRACTURE Quiones-Huayna, Karina Liz; Evangelista-Cabrera, Lourdes Del Rosario; Cabezas- Alfonso, Pilar; Mora-Fernndez, Jess. Department of Geriatrics,


slide-1
SLIDE 1

IMPACT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS ON LONG-TERM MORTALITY AFTER HIP FRACTURE

Quiñones-Huayna, Karina Liz; Evangelista-Cabrera, Lourdes Del Rosario; Cabezas- Alfonso, Pilar; Mora-Fernández, Jesús.

Department of Geriatrics, Hospital Clinico San Carlos, Madrid, Spain.

slide-2
SLIDE 2

CONFLICT OF INTEREST DISCLOSURE

we have no potential conflicts of interest to report

slide-3
SLIDE 3

BACKGROUND

The use of anticoagulants and antiplatelet agents in older people has been rising in relationship to the increasing prevalence of cardiovascular and thromboembolic diseases as appropriate prescription according to STOPP START criteria. Anaemia is mentioned in the literature as a factor associated with increased morbidity and mortality.

slide-4
SLIDE 4

OBJECTIVE

To evaluate the impact of preoperative anticoagulant and antiplatelet therapy on the long-term mortality of hip fracture patients.  To evaluate the predictors by one year mortality.

slide-5
SLIDE 5

Jan 2015 – Feb 2016

METHODS(1)

418 patients

1 year follow-up study Consecutive patients over 65 admitted with hip fracture

Phase 1: Data collection:

 Demographic data.  Functional (Barthel Index, Functional ambulation classification, Lawton index).  Comorbidity (Age-adjusted Charlson comorbidity index ).  Time to surgery .  Use and type of Anticoagulants and antiplatelet agents,  Haemoglobin at admission , lowest haemoglobin level, blood transfusion.  Complications.  length of stay.

Phase 2:

 Mortality at 1-year

follow-up.

n=406

slide-6
SLIDE 6

METHODS(2)

  • STATISTICAL ANALYSIS:

Chi-square and Mann-Whitney U test, Kaplan-Meier survival curves, Cox regression model. SPSS 23.0.

slide-7
SLIDE 7

RESULTS

BASE-LINE CHARACTERISTICS Mean Age 84.9 (SD 7.2) Female 79.9% (334) Age-adjusted Charlson comorbidity index 6.1 (IQR 5.0-7.6) Cognitive impairment 43.5% (182) Barthel Index 85 (IQR 65 - 95) Functional ambulation classification 4 (IQR 3 - 5)

slide-8
SLIDE 8

RESULTS

GENERAL CHARACTERISTICS Time to Surgery (days) 3.8 (IQR 2.1 – 5.3) Length of Stay (days) 9.3 (IQR 6.4 – 14.7) Haemoglobin at admission time(mg/dl) 12.7 (IQR 11.4 -13.7) Lowest Haemoglobin Level(mg/dl) 8.7 (IQR 8.2- 9.7) Haemoglobin at discharge mg(dl) 10.5 (IQR 9.9 -11.1) Preoperative Blood Transfusion 24.7% (103)

slide-9
SLIDE 9

49.8% 15.8% 34.4% USE OF ANTICOAGULANTS AND ANTIPLATELETS AGENTS

NONE ANTICOAGULANTS ANTIPLATELET AGENTS

AAS 100 mg 76.9% AAS 300 mg 9% Clopidogrel 75mg 9% Others 5.1% Acenocoumarol 86.2% NOADs 12.3% LMWHeparin 1.5%

slide-10
SLIDE 10

Univariate Analysis

Variables p

Gender: male P<0.001 > Age p <0.001 > Length of stay p = 0.002 < Barthel index p = 0.004 < Functional ambulation classification p = 0.006 < Lawton index p =0.008 > Age-adjusted Charlson comorbidity index p <0.001 < Haemoglobin at admission p = 0.04 > Complications p <0.001

slide-11
SLIDE 11

Kaplan Meier Analysis

Cummultative survival Mortality rate:

  • 1 month: 4.3%.
  • 6 months: 11.6%.
  • 1 year: 14.1%.

Time in days

slide-12
SLIDE 12

p=0.66 1 month 3 months 6 months 1 year None medication 3.3% 4.3% 7.7% 9.8% Anticoagulants 3.4% 11.9% 13.6% 15.3% Antiplatelets 5.1% 11.3% 14.7% 18.5%

Kaplan Meier Analysis

Time in days Cummultative survival

None medication. Anticoagulants. Antiplatelet agents.

slide-13
SLIDE 13

PREDICTORS OF ONE YEAR MORTALITY IN MULTIVARIATE ANALYSIS.

B Sig Exp (B) Gender: Male 0.781 0.010 2.184 Age-adjusted Charlson comorbidity index 0.254 <0.001 1.289 Impaired renal function 0.975 0.001 2.650 Delirium 0.711 0.030 2.037

slide-14
SLIDE 14

CONCLUSIONS

There was no association between use of anticoagulants and antiplatelet agents and mortality at 1-year follow-up in our sample.  Gender(male), comorbidity, and specific complications (delirium, Impaired renal function) were the main predictive factors of mortality.

slide-15
SLIDE 15

THANK YOU